Inhibitors of Dipeptidyl Peptidase IV - Recent Advances and Structural Views

Author(s): Daniel Hunziker, Michael Hennig, Jens-Uwe Peters

Journal Name: Current Topics in Medicinal Chemistry

Volume 5 , Issue 16 , 2005

Become EABM
Become Reviewer


Prevalence of type 2 diabetes has increased dramatically in the last decades. Current medicines are not yet capable to efficiently prevent or reverse progression of the disease and its associated comorbidities. As a consequence, there is a great need for novel antidiabetic drugs. Treatments of type 2 diabetes that are based on enhanced and sustained action of insulinotropic incretin hormones such as GLP-1 have received much attention in the past years. Treatment strategies include administration of: 1) GLP-1 analogues that are resistant to degradation by the serine protease DPP-IV, and 2) small molecule DPP-IV inhibitors that are able to provide sustained action of endogenous GLP-1, again by preventing its degradation. This review summarizes recent research results for the second approach. It briefly touches upon the advantages that treatment of type 2 diabetes with DPP-IV inhibitors may offer over current medications. In the main section, several important structural classes of DPP-IV inhibitors are described and compared based on literature data. Specific attention is given to the analysis of several X-ray structures of enzyme-inhibitor co-crystals. Finally, as clinical data are steadily emerging for some of the most advanced development candidates, the last section of this review is providing a brief overview of some efficacy data from recent clinical studies with DPP-IV inhibitors.

Keywords: hypoglycemia, GLP-1, peptidomimetics, Cyanopyrrolidines, cyclization, monotherapy

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2005
Page: [1623 - 1637]
Pages: 15
DOI: 10.2174/156802605775009685
Price: $65

Article Metrics

PDF: 12